William Stephen Sightler, DO | |
1100 N. Broad St., Alamo, GA 30411 | |
(912) 568-1731 | |
(912) 568-1701 |
Full Name | William Stephen Sightler |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 1100 N. Broad St., Alamo, Georgia |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1528108545 | NPI | - | NPPES |
00473437D | Medicaid | GA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 034715 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
William Stephen Sightler, DO Po Box 119, Mc Rae, GA 31055-0119 Ph: (229) 868-6100 | William Stephen Sightler, DO 1100 N. Broad St., Alamo, GA 30411 Ph: (912) 568-1731 |
News Archive
Novartis today announced the US Food and Drug Administration approved the expanded use of Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.
With Skin Cancer Awareness Month upon us, Colorado State University researcher Jesse Wilson is accelerating research to improve imaging and detection of melanoma, the most deadly form of skin cancer, and the fifth most common cancer in the United States.
Scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine (WSU SOM) in Detroit will present the world's largest study that shows the long-term results of fast neutron radiotherapy (FNRT) in the treatment of localized prostate cancer. The findings will be formally announced Tuesday, Nov. 2, at the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting
CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.
For some time, researchers have known about disparities in diagnoses and outcomes among breast cancer patients based on race and age. However, they have been challenged to develop a set of criteria that can be used to reliably target drug delivery mechanisms based on an individual patient's tumor.
› Verified 5 days ago
Austin Keith Barrows, MSN, FNP-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 195 N Broad St, Alamo, GA 30411 Phone: 912-568-1731 | |
Dr. Yvonne S Neau, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 195 N Broad St, Alamo, GA 30411 Phone: 912-568-1731 Fax: 912-568-1701 |